DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update
<p>Abstract</p> <p>Lung cancer is the number one cancer killer in the United States. This disease is clinically divided into two sub-types, small cell lung cancer, (10–15% of lung cancer cases), and non-small cell lung cancer (NSCLC; 85–90% of cases). Early detection of NSCLC, whic...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-10-01
|
| Series: | Molecular Cancer |
| Online Access: | http://www.molecular-cancer.com/content/7/1/81 |
| _version_ | 1819202924597739520 |
|---|---|
| author | Laird-Offringa Ite A Alonzo Todd A Anglim Paul P |
| author_facet | Laird-Offringa Ite A Alonzo Todd A Anglim Paul P |
| author_sort | Laird-Offringa Ite A |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Lung cancer is the number one cancer killer in the United States. This disease is clinically divided into two sub-types, small cell lung cancer, (10–15% of lung cancer cases), and non-small cell lung cancer (NSCLC; 85–90% of cases). Early detection of NSCLC, which is the more common and less aggressive of the two sub-types, has the highest potential for saving lives. As yet, no routine screening method that enables early detection exists, and this is a key factor in the high mortality rate of this disease. Imaging and cytology-based screening strategies have been employed for early detection, and while some are sensitive, none have been demonstrated to reduce lung cancer mortality. However, mortality might be reduced by developing specific molecular markers that can complement imaging techniques. DNA methylation has emerged as a highly promising biomarker and is being actively studied in multiple cancers. The analysis of DNA methylation-based biomarkers is rapidly advancing, and a large number of potential biomarkers have been identified. Here we present a detailed review of the literature, focusing on DNA methylation-based markers developed using primary NSCLC tissue. Viable markers for clinical diagnosis must be detectable in 'remote media' such as blood, sputum, bronchoalveolar lavage, or even exhaled breath condensate. We discuss progress on their detection in such media and the sensitivity and specificity of the molecular marker panels identified to date. Lastly, we look to future advancements that will be made possible with the interrogation of the epigenome.</p> |
| first_indexed | 2024-12-23T04:11:45Z |
| format | Article |
| id | doaj.art-ad47d3d53bb14f65a3eebf7c237110e0 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-12-23T04:11:45Z |
| publishDate | 2008-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-ad47d3d53bb14f65a3eebf7c237110e02022-12-21T18:00:29ZengBMCMolecular Cancer1476-45982008-10-01718110.1186/1476-4598-7-81DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an updateLaird-Offringa Ite AAlonzo Todd AAnglim Paul P<p>Abstract</p> <p>Lung cancer is the number one cancer killer in the United States. This disease is clinically divided into two sub-types, small cell lung cancer, (10–15% of lung cancer cases), and non-small cell lung cancer (NSCLC; 85–90% of cases). Early detection of NSCLC, which is the more common and less aggressive of the two sub-types, has the highest potential for saving lives. As yet, no routine screening method that enables early detection exists, and this is a key factor in the high mortality rate of this disease. Imaging and cytology-based screening strategies have been employed for early detection, and while some are sensitive, none have been demonstrated to reduce lung cancer mortality. However, mortality might be reduced by developing specific molecular markers that can complement imaging techniques. DNA methylation has emerged as a highly promising biomarker and is being actively studied in multiple cancers. The analysis of DNA methylation-based biomarkers is rapidly advancing, and a large number of potential biomarkers have been identified. Here we present a detailed review of the literature, focusing on DNA methylation-based markers developed using primary NSCLC tissue. Viable markers for clinical diagnosis must be detectable in 'remote media' such as blood, sputum, bronchoalveolar lavage, or even exhaled breath condensate. We discuss progress on their detection in such media and the sensitivity and specificity of the molecular marker panels identified to date. Lastly, we look to future advancements that will be made possible with the interrogation of the epigenome.</p>http://www.molecular-cancer.com/content/7/1/81 |
| spellingShingle | Laird-Offringa Ite A Alonzo Todd A Anglim Paul P DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update Molecular Cancer |
| title | DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update |
| title_full | DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update |
| title_fullStr | DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update |
| title_full_unstemmed | DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update |
| title_short | DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update |
| title_sort | dna methylation based biomarkers for early detection of non small cell lung cancer an update |
| url | http://www.molecular-cancer.com/content/7/1/81 |
| work_keys_str_mv | AT lairdoffringaitea dnamethylationbasedbiomarkersforearlydetectionofnonsmallcelllungcanceranupdate AT alonzotodda dnamethylationbasedbiomarkersforearlydetectionofnonsmallcelllungcanceranupdate AT anglimpaulp dnamethylationbasedbiomarkersforearlydetectionofnonsmallcelllungcanceranupdate |